Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 639863-89-1 | MDL No. : | MFCD11983271 |
Formula : | C10H9N3O2 | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | FDMDQFRWRSOCPC-UHFFFAOYSA-N |
M.W : | 203.20 | Pubchem ID : | 20474283 |
Synonyms : |
|
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501 | UN#: | N/A |
Hazard Statements: | H302-H315-H319-H335 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
93% | With chloro-trimethyl-silane; triethylamine; In pyridine; at 100℃; | Adapting a protocol by Catarzi et al (J. Med Chem., 2001, 44, 3157-3165), [DIFORMYLHYDRAZINE] (352 mg, 4.0 mmol) and then dropwise trimethylsilyl chloride (2.53 mL, 20 mmol) and Et3N (1.30 mL, 9.3 mmol) were added to a suspension of 4- aminophenylacetic acid (201 mg, 1.33 mmol) in anhydrous pyridine. The mixture was heated at [100 °C] overnight, volatiles were removed at reduced pressure and the resulting solid was treated with water (6 mL), collected, washed with [HA0] and dried in [VACUO TO] provide 251 mg (93percent) of 141JP01 as a light brown solid. LCMS m/z 204 [[M+H] +.APOS;H-] NMR (DMSO-d6) [8] 9.05 (s, 2H), 7.62 (d, 1H, J= 8.6), 7.40 (d, 1H, J= 8.2), 3.61 (s, 2H). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
54% | With N-ethyl-N,N-diisopropylamine; bromo-tris(1-pyrrolidinyl)phosphonium hexafluorophosphate In DMF (N,N-dimethyl-formamide) at 20℃; for 2h; | N-{1-[2-(1,3-Dioxan-2-yl)ethyl]piperidin-4-yl}-N-(4-fluorobenzyl)-2-[4(1,2,4-triazol-4- yl)phenyl]acetamide, L-tartrate (141JP13). The acid 141JP01 (35 mg, 0.17 mmol), [N {1- [2- (1,] 3-dioxan-2-yl) ethyl] piperidin-4- [YL}-N-(4-FLUOROBENZYL)] amine [(118AF52-95,] 55 mg, 0.17 mmol) and diisopropylethylamine (52 mg, 0.51 mmol) were dissolved in DMF (5 mL). Bromo-tris-pyrrolidino-phosphonium hexafluorophosphate (PyBroP, 119 mg, 0.25 mmol) was added, and the mixture was stirred at rt for 2 h. The mixture was concentrated and passed onto an acidic ion exchange SPE cartridge. The cartridge was washed with methanol (8x4 mL) and the remaining product was eluted off the column with 10% NH40H in methanol (2x4 mL) and evaporated. The resulting oil was purified as in [121JP34] to give 47 mg (54 %) of [141JP13] as a colourless oil. The L-tartrate salt was prepared as described above. Rf = 0.26 [(MEOH/CH2CL2] 1: 10). LCMS [M/Z] [508] [[M+H] +.'H-NMR (CDC13,] rotamers 0.5 : 0.5) 8 8.47 and 8.41 (2s, 1H, -H), 7.48-6. 89 (m, 8H, Ar-H), 4.62-4. 56 (m, 0.6H, pip-H), 4.56-4. 49 (m, 3H, dioxane-H, benzyl-H), 4.10-4. 01 (m, 2H, dioxane-H), 3.79 and 3.61 (2s, 2H, benzyl-H), 3.77-3. 67 (m, 2.4H, pip-H, dioxane-H), 2.94-2. 84 (m, 2H, pip- H), 2.45-2. 35 (m, 2H, [NCH2),] 2.10-1. 43 (m, 9H, dioxane-H, NCH2CH2, pip-H), 1.37-1. 27 (m, 1 H, dioxane-H). |